Amgen, Inc. (AMGN) EPS Estimated At $3.09

July 17, 2017 - By Adrian Mccoy

 Amgen, Inc. (AMGN) EPS Estimated At $3.09
Investors sentiment decreased to 1.09 in 2016 Q4. Its down 0.17, from 1.26 in 2016Q3. It worsened, as 98 investors sold Amgen, Inc. shares while 488 reduced holdings. 111 funds opened positions while 527 raised stakes. 561.98 million shares or 1.23% less from 568.98 million shares in 2016Q3 were reported.
Goelzer Investment Mngmt holds 0.03% in Amgen, Inc. (NASDAQ:AMGN) or 1,599 shares. Mechanics Comml Bank Trust Department has 0.13% invested in Amgen, Inc. (NASDAQ:AMGN). The Pennsylvania-based Clark Mgmt Grp has invested 1.19% in Amgen, Inc. (NASDAQ:AMGN). Brinker Capital accumulated 0.13% or 16,429 shares. Moreover, Oakwood Mngmt Ltd Limited Liability Company Ca has 1.26% invested in Amgen, Inc. (NASDAQ:AMGN). Mckinley Capital Mgmt Ltd Llc Delaware holds 0.02% or 4,215 shares. Point72 Asia (Hong Kong) Ltd reported 0.02% in Amgen, Inc. (NASDAQ:AMGN). Opus Point Ptnrs Management Ltd holds 18,743 shares or 2.18% of its portfolio. Boston Family Office Lc has invested 0.28% in Amgen, Inc. (NASDAQ:AMGN). Butensky Cohen Fincl Security Incorporated accumulated 4,095 shares. Plancorp Ltd Liability Com holds 10,366 shares. Lumina Fund Mngmt Limited Liability Company holds 0.96% in Amgen, Inc. (NASDAQ:AMGN) or 61,900 shares. Comml Bank invested in 0.13% or 8,049 shares. Mufg Americas Hldgs Corporation has invested 0.41% in Amgen, Inc. (NASDAQ:AMGN). Michigan-based Exchange Management has invested 1.37% in Amgen, Inc. (NASDAQ:AMGN).

Since May 24, 2017, it had 0 insider purchases, and 2 sales for $1.02 million activity. 3,700 Amgen, Inc. (NASDAQ:AMGN) shares with value of $569,541 were sold by BALTIMORE DAVID.

Investors wait Amgen, Inc. (NASDAQ:AMGN) to report on July, 26. its quarterly earnings Wall Street analysts expect $3.09 earnings per share, up $0.25 or 8.80 % from last year’s $2.84 same quarter earnings. This translates into $2.29B profit for AMGN giving the stock a 14.44 P/E. This is assuming the current $3.09 EPS is accurate. Amgen, Inc.’s Wall Street analysts see -1.90 % negative EPS growth, taking into account the $3.15 EPS reproted in the previous quarter, About 2.66M shares traded. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since July 18, 2016 and is uptrending. It has underperformed by 11.43% the S&P500.

Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage

Among 19 analysts covering Amgen Inc. (NASDAQ:AMGN), 9 have Buy rating, 0 Sell and 10 Hold. Therefore 47% are positive. Amgen Inc. had 46 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating by UBS given on Monday, September 7. Mizuho maintained it with “Buy” rating and $19500 target in Friday, July 14 report. The rating was maintained by Oppenheimer on Monday, June 5 with “Buy”. The stock of Amgen, Inc. (NASDAQ:AMGN) earned “Market Perform” rating by Wells Fargo on Friday, December 4. The firm earned “Outperform” rating on Tuesday, December 13 by Oppenheimer. The firm has “Buy” rating by Jefferies given on Tuesday, July 11. The firm earned “Outperform” rating on Wednesday, January 20 by Credit Suisse. Argus Research maintained the shares of AMGN in report on Monday, February 8 with “Buy” rating. The stock of Amgen, Inc. (NASDAQ:AMGN) earned “Hold” rating by Gabelli on Friday, August 26. Bernstein maintained the stock with “Hold” rating in Wednesday, June 7 report.

Amgen Inc. is a biotechnology company. The company has market cap of $132.02 billion. The Firm discovers, develops, makes and delivers various human therapeutics. It has a 16.81 P/E ratio. It operates in human therapeutics segment.

More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: which released: “Amgen: An Undervalued Industry Leader” on June 21, 2017, also with their article: “Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Standout” published on July 14, 2017, published: “Burns JW & Co Inc Buys Amgen Inc, SPDR S&P Dividend, Vanguard REIT ETF – DNQ …” on July 08, 2017. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: and their article: “Amgen Receives FDA Approval For BLINCYTO” published on July 13, 2017 as well as‘s news article titled: “Amgen Is A Buy At These Levels” with publication date: June 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.